APOLLOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2117 USD | -3.77% |
|
+3.02% | -78.06% |
| 06-04 | Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting | CI |
| 05-08 | Apollomics, Inc. Appoints Robert Lin to the Board of Directors | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 130 | 139.1 | 86.4 | 23.23 |
| Enterprise Value (EV) 1 | 130 | 139.1 | 86.4 | 23.23 |
| P/E ratio | -43.2 x | -16.7 x | -0.42 x | -0.33 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 26.8 x | - |
| EV / Revenue | - | - | 26.8 x | - |
| EV / EBITDA | - | -3,117,013 x | -1,560,728 x | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 13,090 | 13,428 | 89,531 | 109,730 |
| Reference price 2 | 9.930 | 10.36 | 0.9650 | 0.2117 |
| Announcement Date | 29/09/22 | 28/04/23 | 28/03/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net sales 1 | - | - | 3.229 | - |
| EBITDA | - | -44.63 | -55.36 | - |
| EBIT 1 | - | -45.4 | -56.02 | -65.26 |
| Operating Margin | - | - | -1,735.06% | - |
| Earnings before Tax (EBT) 1 | - | -240.8 | -172.6 | -65.26 |
| Net income 1 | -94.8 | -240.8 | -172.6 | -65.26 |
| Net margin | - | - | -5,345.34% | - |
| EPS 2 | -0.2300 | -0.6200 | -2.320 | -0.6500 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 29/09/22 | 28/04/23 | 28/03/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -15.5 | -16.06 | -16.58 | -17.12 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.5 | -16.06 | -16.58 | -17.12 |
| Net income 1 | -15.5 | -16.06 | -16.58 | -17.12 |
| Net margin | - | - | - | - |
| EPS 2 | -0.1700 | -0.1800 | -0.1600 | -0.1400 |
| Dividend per Share | - | - | - | - |
| Announcement Date | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | 0.37 | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 29/09/22 | 28/04/23 | 28/03/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2117
USD
Average target price
2
USD
Spread / Average Target
+844.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -78.06% | 23.23M | |
| +16.45% | 122B | |
| +21.96% | 116B | |
| +23.73% | 27.03B | |
| -20.05% | 20.36B | |
| -16.28% | 15.91B | |
| -16.52% | 16.43B | |
| -44.35% | 15.6B | |
| +63.91% | 14.94B | |
| +2.52% | 13.59B |
- Stock Market
- Equities
- APLM Stock
- Financials Apollomics, Inc.
